Supernus Pharmaceuticals Property, Plant, and Equipment 2011-2024 | SUPN
Supernus Pharmaceuticals property, plant, and equipment from 2011 to 2024. Property, plant, and equipment can be defined as the sum of all net property, plant & Equipment fields. Where companies do not report a break down of plant, property, & equipment, the value is entered in this field alone.
Supernus Pharmaceuticals Annual Property, Plant, and Equipment
(Millions of US $) |
| 2023 |
$14 |
| 2022 |
$15 |
| 2021 |
$17 |
| 2020 |
$38 |
| 2019 |
$17 |
| 2018 |
$4 |
| 2017 |
$5 |
| 2016 |
$4 |
| 2015 |
$4 |
| 2014 |
$2 |
| 2013 |
$3 |
| 2012 |
$1 |
| 2011 |
$1 |
| 2010 |
$ |
Supernus Pharmaceuticals Quarterly Property, Plant, and Equipment
(Millions of US $) |
| 2024-09-30 |
$12 |
| 2024-06-30 |
$12 |
| 2024-03-31 |
$13 |
| 2023-12-31 |
$14 |
| 2023-09-30 |
$14 |
| 2023-06-30 |
$14 |
| 2023-03-31 |
$15 |
| 2022-12-31 |
$15 |
| 2022-09-30 |
$16 |
| 2022-06-30 |
$16 |
| 2022-03-31 |
$17 |
| 2021-12-31 |
$17 |
| 2021-09-30 |
$16 |
| 2021-06-30 |
$17 |
| 2021-03-31 |
$38 |
| 2020-12-31 |
$38 |
| 2020-09-30 |
$17 |
| 2020-06-30 |
$18 |
| 2020-03-31 |
$18 |
| 2019-12-31 |
$17 |
| 2019-09-30 |
$10 |
| 2019-06-30 |
$4 |
| 2019-03-31 |
$4 |
| 2018-12-31 |
$4 |
| 2018-09-30 |
$7 |
| 2018-06-30 |
$5 |
| 2018-03-31 |
$5 |
| 2017-12-31 |
$5 |
| 2017-09-30 |
$5 |
| 2017-06-30 |
$5 |
| 2017-03-31 |
$4 |
| 2016-12-31 |
$4 |
| 2016-09-30 |
$4 |
| 2016-06-30 |
$4 |
| 2016-03-31 |
$4 |
| 2015-12-31 |
$4 |
| 2015-09-30 |
$3 |
| 2015-06-30 |
$3 |
| 2015-03-31 |
$2 |
| 2014-12-31 |
$2 |
| 2014-09-30 |
$3 |
| 2014-06-30 |
$3 |
| 2014-03-31 |
$3 |
| 2013-12-31 |
$3 |
| 2013-09-30 |
$2 |
| 2013-06-30 |
$2 |
| 2013-03-31 |
$2 |
| 2012-12-31 |
$1 |
| 2012-09-30 |
$1 |
| 2012-06-30 |
$1 |
| 2012-03-31 |
$1 |
| 2011-12-31 |
$1 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
